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ABSTRACT
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor
remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting
in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug
resistance and improve the efﬁcacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget
tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced
renal carcinoma and radioactive iodine-resistant thyroid carcinoma. Unfortunately, sorafenib showed very
modest effects in a multi-institutional phase II trial in advanced uterine carcinoma patients. Here, by
leveraging RNA-sequencing data from the Cancer Cell Line Encyclopedia and cell survival studies from
compound-based high-throughput screenings we have identiﬁed the lysosomal pathway as a potential
compartment involved in the resistance to sorafenib. By performing additional functional biology studies
we have demonstrated that this resistance could be related to macroautophagy/autophagy. Speciﬁcally,
our results indicate that sorafenib triggers a mechanistic MAPK/JNK-dependent early protective
autophagic response in EC cells, providing an adaptive response to therapeutic stress. By generating in
vivo subcutaneous EC cell line tumors, lung metastatic assays and primary EC orthoxenografts
experiments, we demonstrate that targeting autophagy enhances sorafenib cytotoxicity and suppresses
tumor growth and pulmonary metastasis progression. In conclusion, sorafenib induces the activation of a
protective autophagic response in EC cells. These results provide insights into the unopposed resistance of
advanced EC to sorafenib and highlight a new strategy for therapeutic intervention in recurrent EC.
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Introduction
Endometrial cancer (EC) is the most common gynecologic
malignancy in the Western world with more than 280,000 cases
per year worldwide.1,2 The incidence of EC has increased by
21% since 2008 and about one in 37 women will develop it dur-
ing their lifetime.2,3
Histological and pathological evaluation classiﬁes EC into
type I (endometrioid) and type II (nonendometrioid) tumors
(Bokhman’s classiﬁcation).4 Type I ECs are low grade, estrogen-
dependent tumors that originate from pre- or peri-menopausal
women. Type II ECs are very aggressive, estrogen-independent
tumors that arise in older women and present a worse outcome
when compared with type I lesions. Recently, a new classiﬁca-
tion based on molecular proﬁling of EC has shed light into the
different genomic subtypes of EC with the potential to improve
and predict new postsurgical adjuvant treatments.5
Prognosis for EC at early stages, when primary surgical
resection is often curative, is excellent, leading to 5-y survival
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rates of over 70%. Unfortunately, 15–20% of EC cases recur
after surgery to vaginal or pelvic regions, often metastasizing to
distant sites.6,7 Patients showing high-risk tumor features (high
grade, deep myometrial invasion, cervical involvement) receive
adjuvant radiation, chemotherapy or both. However, these
treatments are estimated to beneﬁt only 10–15% of all patients.8
Consequently, the prognosis of patients with recurred or
advanced (metastatic) EC is poor with median survival rates of
less than one y.9 Current response rates to molecularly targeted
drugs are poor in relapsed EC and the urge for the development
of improved targeted therapies has become one of the major
concerns.
Figure 1. (For ﬁgure legend, see page 3)
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In recent years, structural and functional evidence has pointed
to tyrosine kinases (TKs) as essential components of tumor pro-
gression by sustaining proliferation/survival of cancer cells, and
thus represent a major pharmaceutical target against cancer.10-12
Unbalanced kinase signaling has primed the development of
molecularly driven targeted compounds aimed at reducing toxic-
ity and for tailored adjuvant and neoadjuvant treatments.
Sorafenib (BAY 43–9006, Nevaxar) is a broad-spectrum
kinase inhibitor with antiangiogenic properties currently
administered in patients with advanced renal cell carcinoma,
hepatocellular carcinoma and most recently in metastatic thy-
roid carcinoma.13,14 Sorafenib was initially designed to inhibit
RAF1, but subsequent studies revealed that its inhibitory action
expanded to other intracellular kinases such as BRAF and
prominent receptor tyrosine kinases (RTKs) such as KDR,
FLT4, KIT, FGFR1, PDGFRA and RET.15,16 Because of its anti-
angiogenic properties, sorafenib has been proposed as a prom-
ising targeted therapy for EC. Several lines of evidence
supported this rationale (e.g., the prominent role of the RAS-
RAF-MAP3K/MEK-MAPK pathway or the increased levels of
VEGFA and angiogenic markers in EC patients).17-19 Unfortu-
nately, very modest effects were observed in a multicenter
phase II trial when tested in advanced uterine carcinoma
patients.20 In the present study we dig into the mechanistic
basis of this resistance and introduce a new approach to
improve sorafenib efﬁcacy in EC patients.
Results
Sorafenib targets EC cells with high speciﬁcity
Given the poor clinical beneﬁts of sorafenib observed in EC
patients we re-evaluated the efﬁcacy of sorafenib in EC. To
address this, we reanalyzed the effects of a panel of TK inhibitors,
including sorafenib, in a high-throughput screening using 494
cancer cell lines.21 We focused our analysis on 12 selective kinase
inhibitors with sensitivity data for EC cell lines. For each drug we
ranked cancer cell lines according to their sensitivity and tested if
EC cell lines are over-represented among sensitive cell lines
(based on gene set enrichment analysis [GSEA], see Materials
and Methods).22 Our analysis revealed that sorafenib was the
most effective compound compromising EC cell viability
(Figs. 1A-C, S1A and S1B). We further explored the effects of
sorafenib on EC cells by analyzing the ability of sorafenib to
decrease the levels of phosphorylated (p-)EIF4E, a hallmark of
sorafenib’s mechanism of action.23-29 Our data indicated that
sorafenib treatment resulted in a dramatic decrease in p-EIF4E
levels (Fig. 1D-F) and compromised EC cell viability and clono-
genic capabilities (Fig. 1G and 1H) by inducing cellular DNA loss
(Fig. 1I), increasing the number of apoptotic cells (Fig. 1J and K)
and triggering caspase activation and PARP (poly[ADP-ribose]
polymerase) proteolysis in different EC cell lines (Fig. 1L). These
results point to sorafenib being an effective anticancer agent
against EC cells in vitro and support previous observations.30,31
Sorafenib induces macroautophagy in EC cells
The discrepancy between our data obtained in vitro and the
poor effects of sorafenib in EC patients prompted us to dissect
the underlying mechanisms of this resistance. The mechanistic
dissection of this phenomenon could entail instrumental
insights that could result in clinical beneﬁts. Previous attempts
to potentiate sorafenib activity have shown that modulation of
antiapoptotic proteins such as CFLAR/FLIP, BCL2L1/BCL-XL,
BCL2 or MCL1 can increase sorafenib cytotoxic activity.30-33
To explore the genetic program associated with sorafenib resis-
tance, we used GSEA to test the association between gene
expression signatures and sensitivity to sorafenib (see Meth-
ods).34 Interestingly, we found signiﬁcant enrichment of genes
encoding lysosomal and catabolic metabolism pathway compo-
nents among those whose expression negatively correlated with
sorafenib sensitivity (Figs. 2A and S2A-S2D).
The lysosomal compartment represents one of the main cel-
lular pathways implicated in the degradation of all sorts of mac-
romolecules. Importantly, lysosomes play prominent roles in
cell secretion, signaling and energy metabolism processes with
the potential to inﬂuence drug response functions.35 Based on
this, we hypothesized that lysosomal activity could be involved
in the resistance to sorafenib in our experimental model and
could be used as a ﬁrst-line approach to further dig into this
phenomenon. First, to study the effects of sorafenib on lyso-
somal function we used a ﬂuorescent acidotropic probe highly
selective for lysosomes to measure pH-dependent changes in
ﬂuorescence intensity upon acidiﬁcation. Our data showed an
increase in ﬂuorescence after sorafenib treatment in EC cells,
indicative of a progressive cellular acidiﬁcation (Fig. S2E). Cor-
rect lysosomal acidiﬁcation is essential to facilitate the digestion
of cellular components via the endocytic or the autophagic
pathways.36 On the basis of these lines of evidence and given
the role of autophagy as a cellular mechanism to cope with
therapeutic stress,37 we aimed to determine whether sorafenib
triggered a cellular autophagic response, a phenomenon that
Figure 1. (see previous page) Sorafenib targets endometrial cancer cells with high speciﬁcity and induces apoptotic cell death. (A) Analysis of sorafenib effects in a high-
throughput screening using kinase inhibitors in a panel of 494 cancer cell lines21 Sensitivity was calculated as the fraction of viable cells relative to untreated controls fol-
lowing treatment with 2mM sorafenib for 72 h21. The sensitivity values of cell lines are plotted as a function of the ranking of the sensitivity (from sensitive to resistant).
Uterus cell lines (red circles) are over-represented among sensitive cell lines. (B) Left, ranking and sensitivity of EC cells to sorafenib among the 494 cancer cell lines. Right,
graphical representation of the ranks, according to decreasing order of sensitivity, among the 494 cell lines analyzed. EC cells are represented as red lines in the top half
of the ranking. Thick bar represents the median rank. (C) Box plot illustrating sorafenib effects in the uterus (n cell lines D 7) compared with the rest of the tissues (18
other tissues, n cell lines D 487). P-value D 6.96e-7 (FDR<1e-5, t-test). For additional information please see Fig. S2B. Other tissues include bladder, skin, bone, brain,
lung, stomach, kidney, thyroid, ovary, pancreas, breast, esophagus, cervix, intestine and liver. Sorafenib effects were assessed in vitro by measuring p-EIF4E levels by west-
ern blot in a dose-dependent treatment (D) and a time-course treatment (E) in Ishikawa cells. Results were further validated in 2 independent EC cell lines (HEC-1A and
RL95–2) at ﬁnal concentration (F). Western blot against tubulin was performed to ensure equal protein loading amounts. MTT assays in Ishikawa, HEC-1A and RL95–2 cells
(G) and clonogenicity assays in Ishikawa cells (H) were performed to measure sorafenib effects on cell viability. Values are represented as the percentage of viable cells or
colonies compared with untreated cells. Sorafenib-induced apoptosis after 24 h of treatment was characterized by measuring DNA fragmentation by ﬂow cytometry (sub
G1 phase) (I), quantifying pyknotic nuclei by Hoechst staining (J) and analysis of ANXA5/Annexin V-positive cells by ﬂow cytometry (K) in Ishikawa cells. (L) Western blot
showing activation of inducer CASP9, executioner CASP3 and PARP cleavage after sorafenib 20mM treatment of 24 h in different EC cell lines. All experiments were per-
formed in triplicate. T test statistical signiﬁcant differences were calculated by comparison to untreated conditions. p< 0.05, p < 0.01, p< 0.001. Scale bar: 100mM.
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has been previously reported in other cell types.33,38-42 To
accomplish these goals we ﬁrst monitored the conversion of
soluble MAP1LC3B/LC3B (LC3B-I) by western blot to phos-
phatidylethanolamine-modiﬁed LC3B (LC3B-II), an autopha-
gosome-associated molecule and a hallmark of autophagy. We
observed an increase in lipidated LC3B in Ishikawa, HEC-1A
and KLE cells after 12 h of sorafenib (20 mM) treatment
(Fig. 2B) and at different concentrations and over time
(Fig. S2F and S2G). These results suggest an increase in auto-
phagosome formation in response to sorafenib. Notably, LC3B-
I to LC3B-II conversion was observed as early as 12 h after
treatment while the effects of sorafenib on cell viability at this
time point were barely detectable (Fig. 1G and 1H) and the
apoptotic rate in Ishikawa cells remained below 10% (Fig. 1J),
Figure 2. (For ﬁgure legend, see page 5)
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indicating that the autophagic response is triggered before the
apoptotic execution.
Previous evidence has shown that, in certain contexts, the
accumulation of autophagosomes or increased levels of LC3B-
II can be attributed to a reduced autophagic ﬂux due to a
reduced fusion of autophagosomes with lysosomes (to generate
autolysosomes) or to a loss of lysosomal digestive function.43,44
In this case, there would not be a bona ﬁde (i.e., complete)
autophagic response characterized by an increased autophagic
ﬂux. To ascertain whether the increase in autophagosome for-
mation observed after sorafenib treatment was caused by I) an
increase in autophagic activity or II) a reduced turnover of
autophagosomes, we arrested the autophagic ﬂux with chloro-
quine (CQ) and with baﬁlomycin A1 (BAF), a lysosomal pH
modiﬁer and a vacuolar-type HC-translocating ATPase inhibi-
tor, respectively, that impair autolysosome formation. Immu-
noﬂuorescence and quantiﬁcation of LC3B-II puncta per cell
point to an increase in autophagosome formation after sorafe-
nib treatment that was further enhanced when the autophagic
ﬂux was arrested with CQ (Figs. 2C and S2H). In addition, we
analyzed the levels of SQSTM1; a scaffolding, receptor and
cargo protein that is incorporated into newly formed autopha-
gosomes and degraded in autolysosomes. Interestingly, while
sorafenib treatment did not result in altered SQSTM1 mRNA
levels (Fig. S2I) it enhanced SQSTM1 proteolysis. Accordingly,
the addition of CQ and BAF blocked the sorafenib-induced
decrease in SQSTM1 levels (Fig. 2D and E), indicating that sor-
afenib increased the autophagic ﬂux. This was further con-
ﬁrmed by monitoring the autophagic ﬂux by using a chimeric
mRFP-GFP tandem ﬂuorescent-tagged LC3B construct
(tfLC3).45 In this assay, and under basal conditions, autophago-
somes are observed as a yellow signal (merged mRFP and GFP
signal). Under increased autophagic conditions the GFP signal
progressively loses ﬂuorescence due to lysosomal acidic and
degradative conditions, but mRFP is relatively resistant, thereby
labeling autolysosomes in red. Hence, induction of autophagy
can be studied by quantifying the increase in both the yellow
and red signals. This assay will allow distinguishing between
increased autophagic ﬂux and conditions that reduce fusion of
autophagosomes with lysosomes, which will typically increase
the yellow signal. Our quantiﬁcation of red (mRFPC GFP¡)
and yellow (mRFPC GFPC) puncta per cell indicates that sora-
fenib increased the autophagic ﬂux (red and yellow puncta),
whereas CQ resulted in the accumulation of yellow puncta
(hence autophagosomes). Rapamycin was used as a positive
control of increased autophagy ﬂux (Fig. 2F).
Altogether, our results point to a consistent induction of
autophagy by sorafenib. These results were complemented by
quantiﬁcation of autophagic structures by transmission elec-
tron microscopy (TEM). Our results indicate that sorafenib
activated the autophagic ﬂux by increasing the formation of
the initial sequestering compartment (the phagophore), the
formation of autophagosomes often containing multivesicular
and multilamellar structures, and autolysosomes (Figs. 2G and
S2J). Finally, because the 3-dimensional (3D) microenviron-
ment can alter autophagy and general intracellular cell signal-
ing when compared with nonpolarized scenarios, we explored
sorafenib’s capacity to activate autophagy in a setting that
more closely recapitulates physiological conditions.46,47 We
assessed sorafenib effects in 3D polarized glandular structures
and subcutaneous tumors using Ishikawa and HEC-1A cells,
respectively. Organotypic cultures displayed typical cell-to-cell,
cell-to-matrix contacts and apical localization of the Golgi
apparatus (Fig. S2K). Interestingly, sorafenib was able to acti-
vate autophagy in 3D cultures and subcutaneous xenografts,
indicating that the sorafenib-induced autophagic response is
maintained in 3D polarized glands and subcutaneous tumors
(Fig. 2H and I).
Sorafenib-induced macroautophagy is dependent on
MAPK8/9/10
Sorafenib induces endoplasmic reticulum (ER) stress, which
can restore cell homeostasis or trigger cell death by simulta-
neously activating multiple interconnected processes such as
the unfolded protein response (UPR), hypoxia or, most impor-
tantly, autophagy.28,48,49 Based on this we hypothesized that, in
our model, an ER stress response may precede the induction of
autophagy by sorafenib. Our results by TEM suggest that sora-
fenib may induce ER stress, as dilated ER lumens were
Figure 2. (see previous page) Sorafenib treatment activates an autophagic ﬂux. (A) Pearson’s correlation coefﬁcients (Y-axis) between gene expression and sorafenib sen-
sitivity of 20 EC cell lines are plotted as a function of the ranking of the coefﬁcients (X-axis). Each data point represents a gene. Gene set enrichment analysis22 shows lyso-
somal genes (red circles) are enriched among those with negative correlation between expression and sorafenib sensitivity. (B) Representative western blot and
densitometry quantiﬁcation from 3 independent experiments showing increased LC3B-II after sorafenib (20mM) treatment of 12 h in Ishikawa, HEC-1A and KLE EC cells.
Western blot against tubulin was performed to ensure equal protein loading amounts. (C) 12-h sorafenib treatment causes an increase in immunoﬂuorescent LC3B-II
puncta per cell that is further increased when sorafenib is combined with CQ, reﬂecting an autophagic response in Ishikawa and HEC-1A EC cells. Left, representative
immunoﬂuorescent images of Ishiwaka cells. Scale bar: 50 mm. Right, quantiﬁcations are represented as percentage of total cell population. Statistical values (t-test) com-
pare the number of LC3B-II puncta per cell between conditions. Autophagic ﬂux arrest using 2 different concentrations of CQ (D) and baﬁlomycin A1 (E). Ishikawa cells
were lysed after 24 h of treatment and levels of SQSTM1 were analyzed by western blot. Western blot against tubulin was performed to ensure equal protein loading
amounts. Densitometry quantiﬁcations of SQSTM1 from 3 independent experiments are also shown. (F) Autophagic ﬂux analysis. Left, representative immunoﬂuorescent
images of Ishiwaka cells transfected with a chimeric mRFP-GFP-LC3B probe showing mRFP, GFP and merged mRFP and GFP (yellow) puncta. Scale bar: 15 mm. Right,
quantiﬁcation of red (mRFPC GFP¡) and yellow (mRFPC GFPC) puncta per cell. (G) Left, schematic illustration of autophagic process with the most relevant autophagic
structures. Right, representative transmission electron microscopy (TEM) images showing formation of phagophores (P), autophagosomes (AP) and autolysosomes (AL)
after sorafenib (20mM) treatment of 24 h. Also, quantiﬁcation of increased P, AP and AL. 100 cells in each condition were quantiﬁed using this method (n D 3). Asterisks
indicate vacuolization and dilated ER cisternae. N, nucleus. (H) Left, representative micrographs of 3D cultures treated with sorafenib showing decreased cytoplasmic con-
tent and the presence of autophagic organelles. Ishikawa cells were cultured in matrigel to form 3D organotypic structures. 3D cultures were left untreated or treated
with sorafenib (20mM) for 24 h and subsequently processed for TEM analysis. M, mitochondria. Right, 3D cultures were additionally processed for western blot against
LC3B-II. LC3B-II densitometry quantiﬁcation from 3 independent experiments are also shown. (I) Left, TEM representative micrographs illustrating autophagy activation in
response to sorafenib in vivo in HEC-1A subcutaneous tumors injected in SCID mice. Images show a drastic depletion of cytoplasmic subcellular compartments and the
presence of autophagic structures. L, lipid droplet. RER, rough endoplasmic reticulum. Xenografts were left to grow for 11 d and mice were injected intraperitoneously
with sorafenib 15 mg/kg/d. At the end of the treatment, tumors were collected and processed for TEM. Right, tissue immunohistochemistry for LC3B (dilution 1:100) and
SQSTM1 (dilution 1:3000). All experiments were performed in triplicate.
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Figure 3. Sorafenib induces autophagy through ER stress and MAPK8/9/10 activation. (A) TEM representative micrographs showing dilated ER cavities in sorafe-
nib-treated Ishikawa cells for 24 h. For additional information please see Fig. S4A. (B) Left, representative images showing increased and discontinuous ﬂuores-
cence intensity in endoplasmic reticulum upon sorafenib treatment. Untreated and sorafenib-treated Ishikawa cells were cultured in the presence of ER-Tracker
Blue-White DPX and analyzed at 4 h post-treatment. Scale bar: 50 mm. Right, quantiﬁcation of ER-Tracker Blue-White DPX intensity according to refs. 94,95 and
using ImageJ software. (C) Left, schematic illustration representing 2 characteristic UPR responses, EIF2AK3/PERK-ATF4 and ERN1/IRE1. Right, XBP1 splicing anal-
ysis by PCR and enzymatic restriction and DDIT3/CHOP protein levels by western blot with densitometry quantiﬁcation in Ishikawa cells treated with sorafenib.
Splicing of XBP1 mRNA results in the excision of a 26-nucleotide intronic region, causing a frame shift in the coding sequence and the removal of a PstI restric-
tion site. Therefore, PstI can digest unspliced XBP1 mRNA (XBP1u), generating XBP1 u1 and u2 fragments, but not spliced XBP1 mRNA (XBP1s). h represents a
hybrid band composed of XBP1u and XBP1s single-stranded DNA produced during PCR. Western blot against tubulin was performed to ensure equal protein
loading amounts. (D) Kaplan-Meyer and (E) disease-free survival curves comparing the outcome of EC cases with or without overexpression of MAPK8/JNK1,
MAPK9/JNK2 and MAPK10/JNK3. A z-score 3 was used as threshold for increased expression. Data were extracted from TCGA_ucec (RNAseq_V2). (F) Western
blot and densitometry quantiﬁcation (n D 3) showing activation of MAPK8/9/10 and its target JUN after a time course treatment of sorafenib (20 mM) in Ishi-
kawa cells. (G) Activation of MAPK8/9/10 and JUN by western blot in sorafenib-treated primary EC biopsies. CEP-1347 inhibits activation of MAPK8/9/10 and
JUN (H) and blocks LC3B-II increase in Ishikawa EC cells (I). Densitometry quantiﬁcations from 3 independent experiments are also shown. (J) Representative
western blot and densitometry quantiﬁcation (n D 3) showing impaired LC3B-II accumulation in mapk8/9¡/¡ cells after sorafenib treatment. (K) Representative
immunoﬂuorescence images and quantiﬁcation of the number of LC3B-II puncta per cell in wild-type and mapk8/9¡/¡ MEFs treated with sorafenib or sorafenib
combined with CQ. Scale bar: 50 mm. (L) Analysis of SQSTM1 protein levels by western blot in wild type and mapk8/9¡/¡ MEFs showing that CQ and Mapk8/9-
targeted deletion abrogates SQSTM1 proteolysis in response to sorafenib in wild-type and mapk8/9¡/¡ MEFs. Western blot against tubulin was performed to
ensure equal protein loading amounts. SQSTM1 densitometry analysis is also shown. All experiments were performed in triplicate.
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frequently observed after treatment (Figs. 2G, 3A, and
S3A).28,48 To test whether this was the case we stained the ER
of EC cells with ER-Tracker, a speciﬁc ER-ﬂuorescent dye com-
monly used to indirectly report ER stress.50-52 Staining of
untreated cells revealed the typical reticular cytoplasmic struc-
ture while sorafenib-treated EC cells displayed an increased
and discontinuous ER intensity (Figs. 3B and S3B). Elevated ER
intensity after treatment occurred before autophagy and apo-
ptosis induction, suggesting that ER stress could precede these
responses. This was further characterized by analyzing molecu-
lar ER stress markers of the UPR such as XBP1 mRNA splicing
and the expression of DDIT3/CHOP. Unspliced XBP1 mRNA
(XBP1u) harbors 2 open reading frames (ORF1 and ORF2)
encoding 2 bZIP proteins of 261 amino acids (aa) and 222 aa,
respectively. Upon activation of ER stress, ERN1/IRE1 removes
a 26-nucleotide intron, containing a PstI restriction site, from
the XBP1 mRNA generating a spliced XBP1 mRNA (XBP1s)
encompassing an open reading frame shift that results in the
production of a potent 376 aa transcription factor. Since PstI
only cuts XBP1u, generating XBP1 u1 and u2 fragments, it is
possible to assess XBP1 mRNA splicing by enzymatic restric-
tion. Our data indicate that as soon as 30 min after sorafenib
treatment the UPR response was activated as measured by
XBP1 splicing and increased DDIT3 protein levels (Fig. 3C)
thus conﬁrming our hypothesis.
ER stress has been linked to autophagy induction in part
through MAPK/JNK, a critical effector of ERN1 signaling.53-55
Importantly, MAPK/JNK has been used to predict poor sorafe-
nib response and increased risk of recurrence in hepatocellular
carcinoma (HCC) patients.56 Thus, we resolved to investigate
the clinical relevance of MAPK/JNK in EC patients and to dis-
sect its role in sorafenib-induced autophagy. Analysis of sur-
vival/recurrence of clinical parameters in EC patients indicated
that increased expression of MAPK8/JNK1, MAPK9/JNK2 and
MAPK10/JNK3 was associated with poor survival and
increased recurrence rates (Fig. 3D and E). Intriguingly, by
using an antibody that recognizes phosphorylation of MAPK/
JNK at residues Thr183/Tyr185, we observed a consistent acti-
vation of MAPK/JNK and the target JUN after sorafenib treat-
ment in EC cell lines and primary EC biopsies. Particularly,
their phosphorylated status reached its peak at 6 h and these
proteins remained phosphorylated even 36 h after treatment
(Figs. 3F, G and S3C). Notably, inhibition of cell death by
increased expression of BCL2L1 and MCL1 abrogated sorafe-
nib-induced apoptosis (Fig. S3D and S3E), but could not pre-
vent activation of MAPK/JNK and JUN (Fig. S3F and S3G),
indicating that their activation was independent of the apopto-
tic execution.30
Finally, to test whether MAPK/JNK activation plays an
instrumental role in the autophagic induction in response to
sorafenib we inhibited their activity with CEP-1347, a selective
inhibitor of the upstream mixed lineage kinase family that does
not block activity of other related kinases such as MAPK/ERK
or MAPK/p38 (Fig. 3H).57,58 Remarkably, addition of CEP-
1347 impaired the increase of LC3B-II after sorafenib treatment
in EC cells (Fig. 3I). To rule out off-target effects of CEP-1347,
we sought to determine the role of MAPK8/9 in wild-type and
mapk8/9¡/¡ mouse embryonic ﬁbroblasts (MEFs) treated with
sorafenib. As shown in Figs. 3J and S3H, targeted deletion of
Mapk8/9 in MEFs completely abrogated MAPK8/9 and JUN
activation in response to sorafenib and signiﬁcantly delayed
LC3B-II accumulation. Analysis of the autophagic ﬂux by
quantiﬁcation of immunoﬂuorescent LC3B-II puncta per cell
(Fig. 3K) and analysis of Sqstm1 mRNA/protein levels (Figs. 3L
and S3I) in wild-type and mapk8/9¡/¡MEFs treated with sora-
fenib or sorafenib plus CQ indicated that MAPK8/9 played an
essential role in the autophagic process. Altogether these results
indicate that sorafenib induces a UPR response in EC cells that
connects with an autophagic output through a MAPK/JNK-
dependent mechanism.
Autophagy inhibition potentiates sorafenib lethality in
vivo
Sorafenib-induced autophagy can promote resistance or trigger
cell death.33,38-42 On the basis of these lines of evidence, we
resolved to dissect its role by inhibiting autophagy in sorafenib-
treated cells. To this end we treated EC cells with sorafenib in
conditions of autophagy inhibition by using CQ. In addition,
we further complemented these data by knocking down
BECN1/Beclin 1 expression using small interfering RNA.
BECN1, the mammalian ortholog of yeast Vps30/Atg6, is an
important regulator of autophagy that is essential for autopha-
gic vesicle nucleation by interacting with the PIK3C3/VPS34
complex and BCL2 homologs.59 Most importantly, BECN1 has
been described as a prognosis factor of poor outcome in endo-
metrial adenocarcinomas.60 By performing cell viability and
apoptosis assays such as ANXA5/annexin-V stainings, quantiﬁ-
cation of picnotic nuclei and western blot against active cas-
pases, our in vitro data showed that autophagy inhibition with
CQ and BECN1 shRNA sensitized EC cells to sorafenib
(Fig. 4A-E and S4A), suggesting that autophagy could be a
counterbalancing mechanism and an adaptive response to
stress.
Next, we aimed to reproduce these results in vivo by testing
sorafenib-CQ combination in HEC-1A subcutaneous tumors.
Interestingly, after 2 wk of treatment we found that combina-
tion of sorafenib with CQ led to a marked reduction in tumor
growth (p < 0.001) with the concomitant decrease in SQSTM1
and increase in LC3B protein levels when compared with sora-
fenib alone (Fig. 4F). We also investigated the ability of sorafe-
nib-CQ to affect lung EC metastatic growth. Metastasis is the
main cause of death in patients with cancer and a critical chal-
lenge in cancer therapeutics. In fact, autophagy represents an
adaptive mechanism during distant tissue colonization, but to
date no reports have evaluated the effects of autophagy inhibi-
tion in developing EC metastases.61 By retro-orbitally injecting
GFP/luciferase-MFE-296 EC cells into SCID (severe combined
immunodeﬁciency) mice, we engineered a lung-EC metastatic
model. Strikingly, while metastases in control, CQ- and sorafe-
nib-treated mice grew unopposed, combined sorafenib-CQ
treatment signiﬁcantly delayed metastatic growth and resulted
in increased survival rates (Fig. 4G and H). Subsequent histo-
logical analyses and quantiﬁcation of metastases sizes revealed
necrotized areas and reduced diameter of metastases (Fig. 4I
and J). These results indicate that autophagy could represent a
cytoprotective mechanism that can potentially be explored
therapeutically in EC.
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Autophagy inhibition potentiates sorafenib effects in
orthoxenograft models and plays a role in EC progression/
recurrence
In recent years autophagy has received increasing attention in
gynecological malignancies, but its function and therapeutic
value is still uncertain.60,62-65 Because the use of conventional
cell lines lacks predictive value in terms of drug development
or clinical testing, we set up a platform to perform sorafenib
translational studies using primary EC-derived orthoxenog-
rafts.66 Orthoxenograft models present the advantage of their
high predictive drug-response value and their accuracy recapit-
ulating the main features of donor tumors including tissue
morphology (Fig. S5A).67 Grade 1-to-3 primary EC samples
Figure 4. (For ﬁgure legend, see page 9)
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were collected, orthotopically implanted in recipient female
mice and the potentiating effects of CQ were assessed using
suboptimal doses of sorafenib (Fig. 5A). Our analyses indicate
that sorafenib-CQ markedly impaired tumorigenesis when
compared with either condition alone (Figs. 5B-D and S5A)
without causing systemic toxicity (Fig. S5B). Altogether these
results indicate that autophagy inhibition using CQ potentiates
sorafenib effects in patient-derived tumor orthoxenografts and
provide insights into the modest effects of sorafenib trials in EC
patients.
Discussion
In this study we have shed light on the mechanisms behind sor-
afenib inefﬁcacy to improve the outcome of advanced and
recurrent uterine carcinoma and carcinosarcoma patients.20
Sorafenib is currently being administered in patients with
advanced renal cell carcinoma, hepatocellular carcinoma and
most recently in metastatic thyroid carcinoma where it has
been shown to improve patient overall survival.13,14,68 Unfortu-
nately, most patients develop disease progression and increas-
ing efforts are dedicated to understand sorafenib resistance at a
mechanistic level.69,70 Initial ﬁndings indicate that acquisition
of sorafenib resistance could involve the activation of compen-
satory mechanisms.71 Using bioinformatics analysis and our in
vitro/in vivo experimental data, we have unraveled autophagy
as a molecular pathway underpinning this resistance in EC.
The induction of a protective autophagic response by sorafenib
has been described previously, but this is the ﬁrst study report-
ing this phenomenon in EC and using patient-derived tumor
orthoxenotransplants.38,72,73 Autophagy is a biologically highly
conserved and regulated catabolic process that recycles macro-
molecules, long-lived proteins and organelles through their
inclusion within double-membrane-bound structures (auto-
phagosomes) and subsequent fusion with lysosomes (to gener-
ate autolysosomes). Here, cargo elements will be hydrolyzed
into basic biomolecules, recycled back to the cytosol and reutil-
ized by anabolic pathways to build new proteins and organ-
elles.74 Recently, autophagy has been shown to be regulated in
normal endometrium across the menstrual cycle and to play a
relevant role in ovarian endometriosis.75-77 However, the
contribution of autophagy and its therapeutic potential in the
development and progression of EC is still underexplored.
By using an array of techniques, our data indicate that sora-
fenib is able to induce a MAPK/JNK-dependent autophagic
response in EC cells that has its origin early during ER stress.
Interestingly, MAPK/JNK can execute autophagy by regulating
the interaction between BECN1 and several members of the
BCL2 family and this could explain why increased MAPK/JNK
activity has been proposed as a predictive biomarker for poor
sorafenib response and increased risk of recurrences in HCC
patients.56,78,79 Similarly, increased MAPK8/JNK1, MAPK9/
JNK2 and MAPK10/JNK3 expression correlates with poor
prognosis in EC patients, suggesting that MAPK/JNK may play
an unforeseen key function favoring EC progression/recur-
rence. Nonetheless, their characterization as instrumental fac-
tors driving EC relapse is still uncertain and warrants
additional investigations.
The role of autophagy during tumor progression and
response to stress is largely unclear and dissecting its biological
function has been demonstrated to be challenging, presumably
because of its context-dependent biology.80 For instance, auto-
phagy is thought to exert tumor suppressor properties in the ini-
tial steps during tumorigenesis by inhibiting necrosis and
consequent immune cell inﬁltration within the primary tumor.
Conversely, autophagy can endow cells the ability to adapt and
to thrive within new hostile environments by protecting cancer
cells from undesired threats at late tumor stages (e.g., vascular
intravasation, extravasation and colonization at distant sites).80
Most importantly, some cancer cells possess the ability to hijack
and tweak the adaptation cues triggered by autophagy to cope
with the stress induced by anticancer treatments.33,37-39,81 There-
fore it is not surprising that, in certain conditions, autophagy
inhibition has been demonstrated to potentiate re-sensitization
to anticancer therapy.81-85 We reasoned that this could be the
case for sorafenib in the context of EC. By inhibiting autophagy
with CQ and BAF our in vitro/in vivo experiments using cell
lines and orthotopic EC patient-derived xenotransplants dem-
onstrate that autophagy may act as a protective mechanism
against sorafenib. Remarkably, this is the ﬁrst report using pri-
mary EC orthoxenografts that addresses autophagy inhibition as
a complementary therapy to sorafenib in cancer samples.
Figure 4. (see previous page) Autophagy inhibition potentiates sorafenib anticancer properties. (A) MTT cell viability assay in sorafenib (SOR)-treated Ishikawa and HEC-
1A cells in combination with chloroquine (CQ) for 12 h. Values are represented as the percentage of viable cells compared with untreated cells. (B) Quantiﬁcation of per-
centage of pyknotic nuclei by Hoechst staining of Ishikawa and HEC-1A cells treated with sorafenib in combination with CQ for 12 h. (C) Analysis of ANXA5/Annexin V-pos-
itive Ishikawa cells by ﬂow cytometry after sorafenib treatment combined with CQ for 12 h. Values are expressed as percentage of cells in relation to total number of cells.
(D) Left, western blot and densitometry quantiﬁcation (n D 3) showing decreased BECN1 expression in BECN1-shRNA infected Ishikawa (IK) cells. Western blot against
tubulin was performed to ensure equal protein loading amounts. Ishikawa cells transduced with lentiviral particles encoding shRNA-scrambled or shRNA-BECN1 and
selected with puromycin. Right, quantiﬁcation of apoptotic nuclei after 2 doses of Sorafenib treatment of 24 h in shRNA-scrambled Ishikawa cells and cells with constitu-
tive decreased expression of BECN1. (E) Western blot showing increased activation of inducer CASP9 and executioner CASP3 in shRNA-BECN1 Ishikawa cells after sorafenib
(20 mM) treatment of 24 h. (F) HEC-1A subcutaneous tumors. Fourteen d after HEC-1A injection, mice were randomized and treated with vehicle (n D 5), CQ 60 mg/kg
(n D 5), sorafenib 15 mg/kg (n D 5) and sorafenib plus CQ (n D 5) and processed at d 29. Top-left, representative image of subcutaneous tumors after treatment. Top-
right, subcutaneous tumor growth kinetics. No differences in tumor size were noticed between vehicle and CQ (1.41 § 0.21cm,3 0.90 § 0.08cm3; p D 0.221), when com-
paring vehicle with sorafenib (1.41 § 0.21cm,3 1.15 § 0.19cm3; p D 0.161) or between CQ and sorafenib (0.90 § 0.08cm,3 1.15 § 0.19cm3; p D 0.447). Notably, combina-
tion of sorafenib with CQ (0.25 § 0.04cm3) led to a marked reduction in tumor volume in all mice (p < 0.001) when compared with either agent alone. Values are
represented as tumor volume fold increase in relation to d 4 after injection. Down, tissue immunohistochemistry for LC3B (dilution 1:100) and SQSTM1 (dilution 1:3000).
All experiments were performed in triplicate. (G) Inhibition of metastatic EC growth by sorafenib combined with CQ. EC cells MFE-296 were stably infected with EGFP-lucif-
erase. After selection, 50£104 MFE-296 cells were retro-orbitally injected and 11 d after injection mice were treated with vehicle (n D 5), CQ 60 mg/kg (n D 5), sorafenib
15 mg/kg (n D 5) and sorafenib plus CQ (n D 5) until d 21 (see Materials and Methods for further details). Left, representative bioluminescence imaging comparing pro-
gression of metastasis in lungs at 15 and 21 d after injection of MFE-296 cells. Right, quantiﬁcation of the relative bioluminescence intensity. Values are expressed as fold
increase in relative luciferase units (RLU) compared with time 0 (11 d post-injection). (H) Kaplan-Meyer survival curve of mice retro-orbitally injected with MFE-296 cells
and treated until d 21. At d 21, treatment was terminated and mice were monitored twice a day. (I) Representative lung morphology analysis by hematoxylin and eosin
staining. Samples were harvested at d 21 based on bioluminescent and survival analysis (n D 5/condition). (J) Quantiﬁcation of metastases diameter.
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Patient-derived orthoxenograft and conventional models
represent an ideal experimental setting to study drug response
treatments. Indeed, several studies point to the high correlation
in the response to conventional anticancer treatments between
the patient and the concomitant personalized xenograft.86,87
Moreover, a high predictive drug response has been demon-
strated when patient therapeutic decision was based on experi-
mental drug screening using personalized tumor graft
models.88 All these determinants have postulated patient-
derived orthoxenografts as an instrumental system in aiding
clinical trial limitations and the development of personalized
medicine.67 Altogether, our results indicate that autophagy
inhibition could represent a good therapeutic strategy to poten-
tiate sorafenib effects in EC and could explain the resistance to
sorafenib observed in advanced or recurred EC patients.
Materials and methods
Reagents and antibodies for western blot
The following reagents were used: chloroquine (Sigma-Aldrich,
C6628), rapamycin (Sigma-Aldrich, R0395), 2,5-diphenyl tetra-
zolium bromide assay (MTT; Sigma-Aldrich, M2128), DMSO
(Sigma-Aldrich, W387520), bisbenzimide H33258 (Sigma-
Aldrich, B2261), anti-tubulin (Sigma-Aldrich, T8203), anti-
DDIT3/CHOP (Sigma-Aldrich, G6916), anti-MCL1 (BD Bio-
sciences, 554103), anti-BCL2L1/BCL-XL (BD Biosciences,
610210), anti-cleaved-CASP9/caspase-9 (Cell Signaling Tech-
nology, 9501), anti-cleaved-CASP3/caspase-3 (Cell Signaling
Technology, 9661), anti-p-JUN/c-Jun (Ser63) (Cell Signaling
Technology, 9261), anti-p-MAPK9/SAPK/JNK (Thr183/
Tyr185) (Cell Signaling Technology, 9251), anti-MAPK9/
SAPK/JNK (Cell Signaling Technology, 9252), anti-p-EIF4E
(Ser209) (Millipore Corporation, 07–823), anti-MAP1LC3B
(H-50; Santa Cruz Biotechnology, 28266), anti-BECN1 (Novus
Biologicals LLC, NB500–249), anti-SQSTM1/p62 (Novus Bio-
logicals LLC, NBP1–48320), and anti-PARP (Neomarkers/
Thermo-Fisher Scientiﬁcs Rockford, RB-1680-P0). Sorafenib
(BAY54–9085) was obtained from Bayer.
Cell lines and 2D culture conditions
RL95–2, KLE and HEC-1A cells were a gift from Dr. Reventos
(Hospital Vall d’Hebron, Barcelona). These cells and the Ishikawa
3-H-12 (Sigma-Aldrich, 99040201) and MFE-296 (Sigma-
Aldrich, 98031101) cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Sigma-Aldrich, 12007559) supple-
mented with 10% fetal bovine serum (FBS; Invitrogen,
10270106), 1 mmol/L HEPES (Sigma-Aldrich, H3375), 1 mmol/L
sodium pyruvate (Sigma-Aldrich, P2256), 2 mmol/L L-glutamine
(Sigma-Aldrich, C59202), 1% penicillin/streptomycin (Sigma-
Aldrich, P4333) at 37Cwith saturating humidity and 5% CO2.
For retro-orbital metastatic assay MFE-296 cells were trans-
fected with the luciferase reporter pLKO.Luc (kindly provided
by Prof Eloi Garı, Institut de Recerca Biomedica de Lleida, Cat-
alonia) and selected with puromycin (Sigma-Aldrich, P7255),
and maintained in regular medium. All experiments were con-
ducted with low passage cells from recently resuscitated frozen
stocks. Cell lines were subjected to comprehensive quality con-
trol and authentication procedures, including short tandem
repeat proﬁling for human cell lines, species veriﬁcation by
DNA barcoding, veriﬁcation of morphology, and testing for
fungi, mycoplasma, and other bacteria.
3D spheroid cultures
Growth of endometrial epithelial cells in 3D cultures was per-
formed as described previously with minor modiﬁcations.89
Figure 5. Autophagy inhibition potentiates sorafenib cytotoxicity in orthotopic patient-derived xenotransplants. (A) Schematic representation of patient-derived orthoxeno-
transplant implants procedure and treatment. EEC tumors were surgically removed and small pieces were implanted in recipient female mice. Once engrafted, tumors were
propagated to a cohort of 20–45 mice, randomized and treated accordingly. Response of engrafted grade-I END72X (B), grade-II END82X (C) and grade-III END90X (D) tumors
after control, sorafenib (30 mg/kg), CQ (60 mg/kg) and sorafenib plus CQ treatments. Animals were treated through 21 d (see Materials and Methods). Graphs illustrate
responses of 3 endometrial orthoxenografts of different histological degree after 21 d of treatment. Representative images of endometrial-engrafted tumors are also shown.
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Brieﬂy, cells were washed with HBSS (Thermo Fisher Scientiﬁc,
11520476) and incubated with trypsin-EDTA solution (Sigma-
Aldrich, T4049) for 3 min at 37C. Trypsin activity was stopped
by adding DMEM containing 10% fetal bovine serum. Cells
were centrifuged at 18£g for 3 min and diluted in DMEM-F12
medium (Sigma-Aldrich, 11580376) containing 3% Matrigel
(BD Biosciences, 354234) and 2% dextran-coated charcoal-
stripped serum (HyClone Laboratories, Inc., 11571821), obtain-
ing 1 £ 104 cell/mL. Cells were cultured for 4–7 d in an incuba-
tor at 37C with saturating humidity and 5% CO2. For
immunoﬂuorescence, cells were seeded in a volume of 40mL
per well in 96-well black plates with a microclear bottom
(Greiner Bio-One, 655090).
Propidium iodide (PI) staining, ANXA5 apoptosis assay and
ﬂow cytometry
Analysis of cell cycle distribution was determined using propi-
dium iodide (PI; Sigma-Aldrich, P4170) staining and ﬂow
cytometry. Following treatment, approximately 1 £ 106 cells
were ﬁxed in 70% ethanol for at least 1 h on ice. Cells were
then resuspended in 2 ml of cell cycle buffer (20 mg/ml PI) in
phosphate-buffered saline (PBS; Sigma-Aldrich, PBS1), con-
taining 0.1% Triton X-100 (Sigma-Aldrich, T8787) and 50 mg/
ml RNase A (Sigma-Aldrich, R5503) for 1 h at 37C. Apoptosis
of human endometrial cells was detected using an ANXA5/
annexin V apoptosis assay (Roche Applied Science, 185777)
followed by ﬂow cytometry analysis. In brief, cells were har-
vested following mild trypsinization, washed in PBS, and
stained with ﬂuorescein isothiocyanate (FITC)-labeled ANXA5
and PI. The percentage of apoptotic cells was evaluated using
FACSCanto II ﬂow cytometer (BD Biosciences, USA), using
the following criteria: (i) viable cells: ANXA5-FITC and PI neg-
ative, (ii) cells in early apoptosis: ANXA5-FITC positive and PI
negative, and (iii) cells in late apoptosis: ANXA5-FITC and PI
positive. PI and ANXA5-FITC ﬂuorescence emission was mea-
sured with a FACSCanto II ﬂow cytometer (BD Biosciences,
USA), and cell cycle distribution was analyzed with WINMDI
2.9 software (The Scripps Research Institute, USA).
XBP1 splicing assay
Total RNA was prepared from the human Ishikawa cell line
using Trizol reagent (Invitrogen, 15596026). mRNA was
reverse-transcribed (RT) to cDNA (42C for 1 h, 50C for 1 h,
and 90C for 10 min) using random hexamers and Superscript
II reverse transcriptase (Applied Biosystems, 18064014). Nega-
tive control RT-minus reactions were carried out to establish
that the target RNA was not contaminated with DNA. The
cDNA product was used as a template for subsequent PCR
ampliﬁcations. The following method was used for detection of
spliced and unspliced mRNAs transcribed from the XBP1 gene.
Brieﬂy the RT-PCR product of XBP1 mRNA was synthesized
primers using primers 50 GGCCTTGTGGTTGAGAACCAG-
GAG 30 (sense) 50 GAATGCCCAA AA GGATATCAGACTC
30 (antisense) with the following PCR protocol: 30 cycles of
PCR ampliﬁcation including initialization at 94C for 4 min,
denaturation at 94C for 10 sec, annealing at 63C for 30 sec,
elongation at 72C for 30 sec, and ﬁnal elongation at 72C for
10 min. Because a 26-bp fragment contains a PstI site that is
spliced upon the activation of XBP1 mRNA, the RT-PCR prod-
ucts were digested with PstI (Takara Bio Inc., 1073A). The
housekeeping gene ACTB/b-actin was used as a loading con-
trol; primers 5 AGAGCTACGAGCTGCCTGAC’ 30 (sense)
and 50 AGCACTGTGTTGGCGTACAG 30 (antisense). Subse-
quent electrophoresis revealed the inactive form as 2 cleaved
fragments and the active form as a noncleaved fragment.
Immunoﬂuorescence
2D or 3D cultures were ﬁxed with formalin for 5 min at room
temperature, and washed twice with PBS. Depending on pri-
mary antibody, cells were permeabilized with 0.2% Triton X-
100 in PBS for 10 min or permeabilized with 100% methanol
for 2 min. Next, cultures were incubated overnight at 4C with
the indicated dilutions of antibodies: anti-CDH1/E-Cadherin
(1:200, Triton X-100; BD Biosciences, 610181); anti-LAM/Lam-
inin (1:500, Triton X-100; Sigma-Aldrich, L9393); anti-
GOLGA2/GM130 (1:100, methanol; BD Biosciences, 610822);
rhodamine-conjugated phalloidin (1:500, Triton X-100; Sigma-
Aldrich, P1951) and anti-MAP1LC3B (1:200, Triton X-100;
Cell Signaling Technology, 2775). After 1 day, cells were
washed twice with PBS and incubated with PBS containing
5mg/mL of Hoechst 33342 and a 1:500 dilution of secondary
anti-mouse Alexa Fluor 546 (Invitrogen, A11005) and Alexa
Fluor 488 (Invitrogen, A11029) or anti-rabbit antibodies Alexa
Fluor 594 (Invitrogen, R37119) and Alexa Fluor 488 (Invitro-
gen, A11034) for 4 h at room temperature. For double-immu-
noﬂuorescence staining, cells were incubated with the second
round of primary and secondary antibodies. In all double-
immunoﬂuorescence stains, ﬁrst and second primary antibod-
ies were from a different isotype. Immunoﬂuorescence staining
was visualized and analyzed using confocal microscopy (model
FV1000; Olympus, Tokyo, Japan) with the £10 and the oil-
immersion £60 magniﬁcation objectives. Analysis of images
was obtained with Fluoview FV100 software (Olympus, Tokyo,
Japan).
Subcutaneous tumor xenografts, retro-orbital injections
and treatment administration
Flank xenograft tumors: immunodeﬁcient 12-wk-old female
SCID hr/hr mice (weight 20–25 g) were maintained in speciﬁc
pathogen-free (SPF) conditions and manipulated in accordance
with institutional guidelines approved by the IRBLLeida
regional committee for animal care. Animals were subcutane-
ously injected with HEC-1A cells (1.5 £ 106) suspended in
100ml PBSCMatrigel (1:1). Tumors were allowed to grow for
14 d. Mice were randomized and treated with an intraperito-
neal injection of chloroquine (60 mg/kg/day) for 2 wk. Sorafe-
nib (BAY 54–9085) was dissolved in a 50% Kolliphor EL
(Sigma-Aldrich, 61791–12–6) 50% absolute ethanol (Scharlau
S.L., ET00061000) mixture to a concentration of 60 mg/mL
and was administered (15 mg/kg/day) by oral gavage for 2 wk.
Tumors were measured 3 times/wk with calipers. Tumor size
was calculated as (D £ d2)/2 Dmm3.
Retro-orbital metastasis model: 50 £ 104 MFE-296 cells
expressing EGFP-luciferase were injected retro-orbitally into
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the sinus of immunodeﬁcient SCID females. Retro-orbital
injections were conducted under 2% isoﬂurane/air anesthesia.
A successful retro-orbital injection was indicated on d 0 by
images showing systemic bioluminescence distributed through-
out the animals; 6–10 animals/group, with evidence of a satis-
factory injection, continued the experiment. 11 d after
injection, when metastases were already noticeable, treatment
was initiated as mentioned. Every 3–4 d we monitored tumor
lesions by Photon Imager (Biospace Mesures; France) coupled
to live imaging software M3 Vision Viewer. For biolumines-
cence tumor imaging, luciferin (Caliper Life Science, 119222)
was used as the substrate for the luciferase expressing tumor
cells and injected intraperitonealy at 150 mg/kg in PBS.
Human tissue samples selection and tissue micro arrays
(TMAs) construction
Three TMAs were constructed using the manual arrayer from
Beecher Instruments Inc., (WI, USA). TMAs contained forma-
lin-ﬁxed, parafﬁn-embedded tissue of 77 primary endometrioid
endometrial carcinomas (ECC) and 24 nonendometrioid endo-
metrial carcinomas (NEEC). A TMA composed of normal
endometrium (24 cases) in different phases of the menstrual
cycle was also included (18 proliferative, 6 secretory). The
tumors were classiﬁed following the most recent WHO criteria.
They were surgically staged and graded according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO) stag-
ing and grading systems. They included 19 grade 1 EECs, 28
grade 2 EECs, and 30 grade 3 EECs. Samples were obtained
from the surgical pathology ﬁles of Hospital Universitari Arnau
de Vilanova, Lleida, Spain (HUAV). The local ethics committee
approved the study and informed consent was obtained from
each patient. All tissue samples were histologically reviewed
and representative tumor or nontumor areas were marked in
the corresponding parafﬁn blocks. Tissue cylinders with a
diameter of 0.6-mm were punched from 2 different tumor areas
of each “donor” tissue block and brought into a recipient paraf-
ﬁn block.
TMA immunohistochemistry
TMA blocks were sectioned at a thickness of 3 mm, dried for
1 h at 65 before the pre-treatment procedure of deparafﬁniza-
tion, rehydration and epitope retrieval in the Pre-Treatment
Module, PT-LINK (DAKO) at 95C for 20 min in 50x Tris-
EDTA buffer (DAKO, K8002), pH 9. Before staining the sec-
tions, endogenous peroxidase was blocked. The antibodies used
were anti-MAP1LC3B (1:100 dilution) and anti-p62/SQSTM1
(1:100 dilution). After incubation, the reaction was visualized
with the EnVisionTM FLEX Detection Kit (DAKO, K8024)
using diaminobenzidine chromogen as a substrate. Sections
were counterstained with hematoxylin. Appropriate negative
controls including no primary antibody were also tested. The
immunohistochemistry was evaluated semi-quantitatively by
the intensity and the presence or not of punctate staining. To
exclude subjectivity, 2 members of the team evaluated all slides
independently. A histological score was obtained from each
sample, which ranged from 0 (no punctate staining) to 3 (maxi-
mum immunoreactivity). Since each TMA included 2 different
tumor cylinders from each case, immunohistochemical evalua-
tion was done after examining both samples.
Analysis of TCGA data
Normalized gene expression data (RNA-Seq z-score) were
downloaded from cBio portal, including 5254 genes and 373
samples.90,91 Each z-score value represents the gene expression
of a sample compared with tumors that have 2 copies of the
gene. Clinical information (overall survival and disease-free
progression) was obtained from. ref. 5. Survival analysis was
performed using Kaplan-Meier estimator and log-rank test.
RNA z-score 3 was used to deﬁne overexpression of a gene to
help stratify patients in survival analysis. To test for differential
survival due to potential MAPK/JNK activities, we stratiﬁed
patients according to overexpression of MAPK8/JNK1,
MAPK9/JNK2 or MAPK10/JNK3.
Analysis of drug sensitivity data
We obtained the cell-line sensitivity to kinase inhibitors from
McDermott et al.21 We focused our analysis on the 12 drugs
with sensitivity data for uterus cell lines. The total number of
cell lines with the sensitivity data are between 493 and 500,
depending on the drugs. To test if uterus cell lines are sensitive
to a drug, GSEA was applied.22 For each drug, we ranked cell
lines according to their sensitivity and test if uterus cell lines
are over-represented among sensitive cell lines. We used 1000
permutations to assess the signiﬁcance of enrichment. In addi-
tion, a t test was used to test if uterus cell lines (n D 7) have dif-
ferential sensitivity compared with all other cell lines (n D 487).
Additionally, we obtained the gene expression (microarray)
and drug sensitivity data of cell lines derived from endome-
trium (n D 20) from Barretina et al.34 Gene expression data
were processed with the MAS5 algorithm.92 Probes hybridized
to multiple genes were discarded. The data were log2 trans-
formed and probes with low (< 6, log2 scale) or high (> 15.5)
values in >20% of the samples were discarded. Data were nor-
malized according to the 75th percentile of each sample. Gene-
level expression was obtained by averaging values of probes
hybridized to the same gene. Genes with low variance (SD <
0.7) were discarded. We then calculated Pearson’s correlation
coefﬁcients between the expression of each gene (6578 genes
after the above ﬁltration) and the sensitivity to sorafenib (activ-
ity area).34 GSEA was used to identify biological processes
(Gene Ontology)93 that are enriched for genes whose expres-
sion are positively or negatively correlated with sensitivity to
sorafenib (1000 permutations).
Generation of orthoxenografts of endometrial
carcinomas in mice
Three endometrial orthoxenografts (endometrioid carcinomas
from different histological degree) were selected from a previ-
ously established library of 75 endometrial orthoxenografts
(ENDX) developed in nude mice after ortothopic implantation
of small pieces of primary human fresh surgical specimens (A.
Vidal and A. Villanueva, unpublished data). To generate the
library, the tumors were obtained at Hospital Universitari de
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Bellvitge (L’Hospitalet de Llobregat, Barcelona,Spain) between
2010 and 2015. Nonnecrotic tissue fragments (ca. 2-3 mm3)
from resected tumors were selected and placed in DMEM
medium supplemented with 10% FBS and penicillin/strepto-
mycin at room temperature. Under isoﬂuorane-induced anes-
thesia, animals (n D 2 to 4) were subjected to a lateral
laparotomy, their uterus exposed and tumor pieces anchored
with prolene 7.0 sutures, and the abdominal incision was
closed with surgery staples. Tumor growth was monitored
twice per wk and when the tumor grew, it was harvested, cut
into small fragments, and transplanted into 2 to 4 new ani-
mals. Engrafted tumors at early mouse passages (#1 to #3)
were cut in 6- to 8-mm3 pieces and stored in liquid nitrogen
in a FBS-based solution and 10% dimethyl sulfoxide for subse-
quent implantation.
Three endometrial orthoxenografts (grade-I ENDX72,
grade-II ENDX80, grade-III ENDX90) were selected from the
library, and they were defrosted, washed several times in
DMEM medium supplemented with 10% FCS and penicillin/
streptomycin, and newly re-implanted in the uterus of 3 young
nude mice. After an elapsed time of 2–3 mo, tumors grew as
orthotopic implants in nude mice, and they were passed to 5
animals (pre-experiment). Animals were housed in a sterile
environment, cages and water were autoclaved, and bedding
and food were g-ray sterilized. A good histology correlation
was seen between primary and xenografted tumors, as along
different mouse-to-mouse passages. None of the endometrial
cancer patients had received previous cytotoxic chemotherapy
treatment. All patients gave written consent to participate in
the study and the Ethics Committee of hospitals cleared the
study protocol; animal experimental design was approved by
the IDIBELL animal facility committee.
Drug response assay in endometrial orthoxenografts
For each tumor, small fragments of 2–5 mm3 of xenografted
tumors obtained in the previous pre-experiment were re-
implanted in one of the arms of the uterus of 30 female nude
mice as described above. When tumors reached a homogeneous
palpable size (10 d for ENDX90; 35 d for ENDX82; and 52 d for
ENDX72) they were randomly allocated into the treatment
groups (n D 5–9/group): i) placebo; ii) sorafenib (30 mg/kg);
iii) chloroquine (60 mg/kg); and iv) sorafenib plus cloroquine
(30C60 mg/kg). Animals were treated daily during 21 d with
chloroquine (administered 1 h before by intraperitoneal injec-
tion), whereas for sorafenib (oral gave) we followed a schedule
of 2 d ON, 1 OFF to reduce drug-induced toxicity. At d 23, ani-
mals were killed, their uterus dissected out, and tumors
weighed and measured with a caliper. Representative fragments
were either frozen in nitrogen or ﬁxed and then processed for
parafﬁn embedding. Additionally, the lungs, liver and dia-
phragm tissues were taken for histological study of the presence
of metastases.
Statistical analysis in vivo experiments
Values are presented in the graphs as the mean § standard
errors of the mean (SEM) of n cell-based experiments or n
biopsies where each value is the average of responses in
triplicate, at least. Statistical analysis was performed with
GraphPad Prism 6.0. Differences between 2 groups were
assessed by the Student t test. Differences between more than 2
groups were assessed by ANOVA, followed by the Tukey’s mul-
tiple comparison test. p < 0.05, p < 0.01 and p < 0.001
were considered statistically signiﬁcant.
Transmission electron microscopy
Cut samples (roughly 2 mm3) were immersed in 2.5% glutaral-
dehyde, 0.1 MPBS, pH 7.4 for 12 h at 40C, postﬁxed for 2 h in
1% osmium tetroxide, dehydrated in acetonitrile and embedded
with Embed-812 epoxy resin (Electron Microscopy Sciences,
14120). Ultrathin sections of 80 nm were counterstained with
uranyl acetate and lead citrate and observed in a Zeiss EM 910
(Zeiss) electron microscope.
Clonogenicity assay
Cells were seeded onto 6-well plates at a density of 1 £ 103 cells
per dish. Twenty-four h later, cells were treated for the indi-
cated hours after which the medium was changed and cells
incubated at 37C in 5% CO2 for 15 d. Colonies were stained
with 0.4 mg/mL MTT ﬁnal concentration for 30 min, ﬁxed in
100% methanol (VWR International, 1060092500) for 5 min
and maintained in 2 mL PBS. Colonies consisting of > 50 cells
were scored using the Quantity One software (Bio-Rad Labora-
tories, USA).
Total RNA extraction, reverse transcriptase-polymerase
reaction (RT-PCR) and quantitative real-time qRT-PCR
Total RNA was extracted from the indicated cell lines using the
RNeasy Total RNA kit (Qiagen, 74104). mRNA was reverse-
transcribed (RT) to cDNA (42C for 1 h, 50C for 1 h, and
90C for 10 min) using the High Capacity cDNA Archive Kit
(Applied Biosystems, 4368813). Negative control RT-minus
reactions were carried out to establish that the target RNA was
not contaminated with DNA. The cDNA product was used as a
template for subsequent PCRTaqman technology from
Applied Biosystems was used for real-time qRT-PCR analyses.
Human Probes: GAPDH, Hs99999905_m1; p62/SQSTM1,
Hs00177654_m1. Mouse Probes: Gapdh, Mm99999915_g1;
p62/sqstm1, Mm00448091_m1. For qRT-PCR assay the cDNA
was ampliﬁed by heating to 95C for 10 min, followed by 40
PCR cycles of 95C for 15 sec and 60C for 1 min using
GoTaq qPCR Master Mix (Promega Corporation, A6001)
and ABI Prism 7900 Sequence Detection System (Applied Bio-
systems, USA). Relative mRNA expression levels were calcu-
lated using the 2DDCt method and are presented as ratios to
the housekeeping gene GAPDH. Each sample pool was ampli-
ﬁed in triplicate using GAPDH for normalization.
ER stress analysis
Cells were incubated with diluted 1:1000 ER-Tracker Blue-
White DPX (Molecular Probes, E12353) in DMEM medium.
Pre-warmed (37C) probe-containing medium was added to
the cells and incubated for 30 min. Thereafter, loading solution
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was removed and cells were washed with PBS before adding
fresh medium without probe. Cells were analyzed using a ﬂuo-
rescence microscope and a confocal laser scanning microscope
model FV1000-Olympus, at £10 and £60 magniﬁcation objec-
tives. Analyses of images were obtained with Fluoview_FV100
software. We have quantiﬁed the intensity of ER staining as
previously performed using the ImageJ software.94,95
mRFP-GFP tandem ﬂuorescent-tagged LC3B (tfLC3)
autophagic ﬂux assay
Ishikawa cells were transfected with tfLC3 plasmid (kindly pro-
vided by Dr. Tamotsu Yoshimori, Osaka University, Japan45)
and left to grow overnight before treatment with sorafenib
(20 mM), chloroquine (10 mM) and rapamycin (500 nM) dur-
ing 12 h. After this period, cell were ﬁxed with paraformalde-
hyde solution (4% in PBS), washed twice with PBS and
analyzed with a confocal laser scanning microscope (Olympus,
FV1000). Images were acquired randomly and cells displaying
intermediate total mRFP-GFP ﬂuorescence were chosen for
analysis. Each channel was acquired by a separate scan avoiding
bleedthrough. We analyzed all cells using the same threshold
settings across all images from each channel. Double mRFP-
GFP puncta were determined using the Colocalization plugin
in ImageJ. All puncta were quantiﬁed using the Analyze Parti-
cle plugin in ImageJ.
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